News

Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, emerges from stealth with $85 million in financing. Stylus’…
Read More...

GSK plc and Boston Pharmaceuticals announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is…
Read More...

Tempus AI, Inc. announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two…
Read More...

AbbVie and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, announced a collaboration and license option agreement to…
Read More...

Recipharm and ProductLife Group (PLG) announced a strategic collaboration aimed at supporting (bio)pharmaceutical companies in accelerating time to clinical trials and market approval…
Read More...

Roche, the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today statistically significant final overall…
Read More...

AstraZeneca’s inhaled medicine Trixeo Aerosphere has become the first pressurised metered-dose inhaler (pMDI) to be approved in the UK using a next-generation propellant with near-zero…
Read More...

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced…
Read More...

Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a…
Read More...

Novo Nordisk presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was non-inferior to the once-daily growth hormone Norditropin…
Read More...

Amneal Pharmaceuticals, Inc. and Apiject Systems, Corp. announced a strategic collaboration to expand domestic production of Apiject’s BFS-based injectable platform at Amneal’s…
Read More...

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common,…
Read More...

Genezen and Optieum Biotechnologies, Inc. (Optieum) announced a partnership for cGMP manufacturing of the lentiviral vector (LVV) construct used in the production of OPTF01, a novel…
Read More...

Adcentrx Therapeutics, a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, announced that…
Read More...

Opus Genetics, Inc. a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders,…
Read More...

BioVaxys Technology Corp. and Sona Nanotech Inc. have announced a research collaboration to develop innovative cancer therapeutics by combining BioVaxys' DPX immune-educating platform…
Read More...

Novo Nordisk has announced that the FDA has accepted the New Drug Application (NDA) for a once-daily 25 mg oral formulation of Wegovy (semaglutide) for chronic weight management in…
Read More...

TAE Life Sciences and The Ohio State University Comprehensive Cancer Center have announced a landmark collaboration focused on advancing boron-based drug innovation for Boron Neutron…
Read More...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™…
Read More...

VERAXA Biotech AG, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp., announced a co-discovery alliance with…
Read More...